To investigate whether the anti-tumor effect was associated with the depleted cancer stem cells in celecoxib-treated hepatoma, immunofluorescence analysis reveale that the significantly decreased prevalence of CD133+/CD44+ hCSCs in celecoxib-treated hepatoma than control group (Fig. 4A). This evidence concerns the gene CD44 and cancer.